Ireland
--:--IST
Latest
Clinical Trials in Italy / NCT07194018
Active, not recruiting Observational

Use of Cannabis Oil in Fibromyalgia

NCT07194018 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-10-19
Last updated
2025-09-26

Condition(s) studied

FibromyalgiaPain ManagementCannabisRetrospective Studies

Investigational drug(s) / intervention(s)

Use of cannabis oil

Use of cannabis oil: Use of cannabis oil on pain relief in patients suffering from fibromyalgia syndrome

Study summary

Recently, medical cannabis has been shown to be effective in chronic pain conditions such as osteoarthritis, neuropathic pain, and other chronic non-cancer pain.

A study showed that fibromyalgia patients who use cannabis report significant improvement in pain symptoms and quality of life. Patients reported a 50% reduction in pain, and many also reported improvements in sleep and overall well-being. Further research found that the use of medical cannabis among patients with fibromyalgia led to significant improvements in pain, sleep quality, and overall quality of life. This study emphasized that adverse effects were generally mild and tolerable. Furthermore, the systematic review by Fitz et al. concluded that cannabis may be effective in treating fibromyalgia, with preliminary evidence indicating improvements in pain and sleep disturbances. However, it also highlighted the need for further randomized controlled trials to confirm these findings and determine how the cannabinoid system interacts with the pain pathway.

Considering that medical cannabis is effective in treating a variety of symptoms, including pain, cachexia and wasting, sleep disorders, severe or persistent muscle spasms, reduced fatigue in multiple sclerosis, chemotherapy-induced nausea, convulsive disorders, post-traumatic stress disorder, and other conditions in palliative and end-of-life care; with this study, given the premises of the effects of medical cannabis, the aim is to analyze its use also in chronic pain as the main symptom of fibromyalgia syndrome.

Eligibility

Sex
ALL
Min age
21 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * written informed consent; * age ≥ 21 years; * diagnosis of FM according to the 2016 American College of Rheumatology (ACR) diagnostic criteria; * failure of previous therapies. Exclusion Criteria: * psychiatric disorders, * history of drug or alcohol addiction, * fatty liver disease or severe liver disease, * severe cardiopulmonary disease, * severe renal failure, * pregnancy or breastfeeding.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical Trial Center Alessandria Piedmont

More Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07194018 on ClinicalTrials.gov ↗ ← All trials in Italy